STAT13d
Pharmalittle: We’re reading about a Merck drug-label controversy, Astellas pulling an application, and more
A drug against fungal infections in cancer patients can last twice as long in people with obesity, and may make chemotherapy ...
Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
Merck: An Undervalued Dividend Machine
Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...
The Motley Fool on MSN9d
Is Merck Stock a Buy?
Understanding the investment thesis for Merck requires appreciating the importance of its blockbuster cancer drug, Keytruda, ...
Canada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has ...
Merck Q3 Earnings & Sales Top, Stock Down on Lowered '24 View
MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales ...
NBC 6 South Florida10d
Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its ...